Samyang Biopharm’s Croquis signs contract for its entry in 12 countries around MENA

June 4^th 2020

- Croquis to be supplied in 12 nations around MENA through Amico, Leader in Healthcare Specialty Markets in MENA Region

- Expected to begin sales by March 2021 … Registration in Brazil, Mexico, Russia ongoing

- Focus on research collaboration with global doctors to conduct evidence-based marketing

Samayang Biopharm signed its supply contract with Amico, an expert medical device distributor and manufacturer in the Middle East for the entry of its medical aesthetic product ‘Croquis’ in the MENA region. Croquis is a drawing technique of quickly describing the characteristics of an object or person using a single line.

Amico established a close sales network among twelve countries around MENA including Saudi Arabia, Iran, and Egypt. Amico’s revenue surpassed 350 million USD in 2019.

Amico will focus on the registration of Croquis in these twelve countries in correspondence with the contract and hopes to begin sales in March 2021.

Samyang Biopharm received its CE mark with Croquis in 2019 and officially executed its global marketing strategy. On the sideline, registration process in Brazil, Mexico, and Russia are ongoing. Mexico registration is expected to be completed by the second half of 2020, followed by Brazil and Russia by 2021.

“Our contract with Amico was a synergy by entering twelve countries at once”, said an official from Samyang, and added that “Samyang will focus on gathering evidence-based scientific data by conducting research collaboration with its KOLs(Key Opinion Leader) and other doctors from all around the world”.

Samyang Biopharm is currently focusing on rheological and clinical studies with Croquis to prove the close relationship between biophysical components of PDO thread and actual clinical results.